BDTXHIGH SIGNALFINANCIAL10-K

BDTX achieved a dramatic turnaround from significant losses to profitability, with net income swinging from -$69.7M to +$22.4M and operating cash flow moving from -$62.3M to +$29.6M.

This represents an extraordinary financial reversal for a clinical-stage biotech company, suggesting either a major milestone payment, asset sale, or other significant non-recurring event that generated substantial cash inflows. The company has simultaneously strengthened its balance sheet with increased stockholders' equity and reduced liabilities, while maintaining its clinical operations as evidenced by continued R&D spending, albeit at reduced levels.

Comparing 2026-03-16 vs 2025-03-06View on EDGAR →
FINANCIAL ANALYSIS

BDTX experienced a remarkable financial transformation, moving from substantial losses to strong profitability across all key metrics - net income improved by $92.1M, operating income by $91.3M, and operating cash flow by $91.9M. While cash declined by $15.4M to $21.0M, the overall balance sheet strengthened significantly with stockholders' equity increasing 34.7% and total liabilities decreasing 21.7%. The dramatic improvement in profitability and cash generation, combined with reduced R&D expenses, suggests either a major business development transaction or significant milestone achievement that has fundamentally altered the company's near-term financial trajectory.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+147.5%
-$62.3M→$29.6M

Operating cash flow surged 147.5% — exceptional cash generation, highest quality earnings signal.

Net Income
P&L
+132.1%
-$69.7M→$22.4M

Net income grew 132.1% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+115.9%
-$78.8M→$12.5M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Cash & Equivalents
Balance Sheet
-42.4%
$36.4M→$21.0M

Cash declined 42.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Stockholders Equity
Balance Sheet
+34.7%
$83.3M→$112.2M

Equity base grew 34.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

R&D Expense
P&L
-34.6%
$51.3M→$33.6M

R&D spending cut 34.6% — could signal cost discipline or concerning reduction in innovation investment.

Current Assets
Balance Sheet
+30.9%
$101.2M→$132.4M

Current assets grew 30.9% — improving short-term liquidity or inventory/receivables build.

Current Liabilities
Balance Sheet
-23.5%
$20.6M→$15.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-21.7%
$39.4M→$30.8M

Liabilities reduced 21.7% — deleveraging improves balance sheet strength and financial flexibility.

Total Assets
Balance Sheet
+16.6%
$122.6M→$143.0M

Asset base grew 16.6% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-06
ADDED
As of March 11, 2026, the registrant had 57,288,750 shares of common stock, $0.0001 par value per share, outstanding.
We may find it difficult to enroll patients in our Phase 2 clinical trial for silevertinib in patients with newly diagnosed EGFR-altered glioblastoma (GBM) or our future product candidates.
We have entered into a license agreement and may form or seek further collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such collaborations, alliances or licensing arrangements.
federal government shutdown or reduced resources, new or increased international tariffs and retaliatory tariffs, new laws and regulations or amendments to existing laws and regulations in the U.S.
and foreign countries, trade protection measures, economic sanctions and economic slowdowns or recessions that may result from such developments which could harm our research and development efforts as well as the value of our common stock and our ability to access capital markets; and other material risks and uncertainties, including those discussed in Part I, Item 1A, Risk Factors in this Annual Report.
+7 more — sign up free →
REMOVED
As of February 28, 2025, the registrant had 56,662,222 shares of common stock, $0.0001 par value per share, outstanding.
We may find it difficult to enroll patients in our Phase 2 clinical trial for BDTX-1535 or our future product candidates with the genetic mutations that these product candidates are designed to target.
If we are unable to obtain and maintain patent and other intellectual property protection for BDTX-1535, BDTX-4933, BDTX-4876, our MAP drug discovery engine and our other product candidates and technology, or any other product candidates or technology we may develop, or if the scope of intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize BDTX-1535 or any of our future product candidates or technology may be adversely affected.
We may form or seek collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such collaborations, alliances or licensing arrangements.
Data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →